Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
ROS 1 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
ROS 1 Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2024
ROS 1 is Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene. This proto-oncogene, highly expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor. Mechanism of action (MOA) of ROS 1 Inhibitor is a substance that blocks the activity of an abnormal protein called ROS1 fusion protein, which is found in some types of cancer cells. Blocking the ROS1 fusion protein may help keep cancer cells that have it from growing and spreading.
Some ROS1 inhibitors are used to treat cancer. They are a type of targeted therapy. ROS 1 inhibitors are used to treat lymphoma, tumors, leukemia, sarcoma, neutropenia, granuloma, lung neoplasm, ocular melanoma, respiratory tract diseases, breast diseases, etc. Increased prevalence of leukemia, sarcoma, and early cancer diagnosis are the key drivers for the ROS 1 Inhibitor market. For instance, according to the Centers for Disease Control and Prevention 2020, Around 1,603,844 new cancer cases were reported in the United States. Launch of newer products by the market players could seek opportunities that influence research and development in ROS 1 Inhibitor. For instance, Pfizer’s Xalkori (Crizotinib) is used to treat carcinoma and neoplasm. Moreover, the development of novel molecules by market players is coming up to overcome challenges in therapy. For instance, Eli Lilly’s Merestinib (LY2801653) for colonic diseases and lymphoma is under the various stages of clinical studies.
Approved Drug Molecules and Brand Names for ROS 1 Inhibitor:
Drugs under the Pipeline for ROS 1 Inhibitor:
Clinical Activity and Developments of ROS 1 Inhibitor:
Till June 2023, more than 28 companies have approximately 22 molecules targeting above 124 diseases. For these molecules, more than 316 clinical trials are being conducted and majority are in phase-2 and phase-3 clinical trials by players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Merestinib (LY2801653) |
11 |
|
Taletrectinib (AB-106) |
8 |
|
Iruplinalkib (WX-0593) |
7 |
|
Repotrectinib (TPX-0005) |
7 |
|
XZP-3621 |
6 |
The molecules such as Xalkori (Crizotinib) developed by Pfizer for the line of treatment to treat non-small cell lung cancer (NSCLC) that is positive for a specific genetic mutation called anaplastic lymphoma kinase (ALK). Takeda’s Alunbrig (Brigatinib) is used for the treatment of adults with non-small cell lung cancer (NSCLC). Roche’s Rozlytrek (Entrectinib) is used for the treatment of cancers with specific gene changes. Moreover, Eli Lilly’s Merestinib (LY2801653) is under development for indications like Lymphoma, mantle cell lymphoma, and colonic disorders.
Total global sales of Pfizer’s Xalkori (Crizotinib) were US$493 million in FY2021 and it was decreased by 9% compared to FY2020. The US market has sales of US$102 million, developed Europe has sales of US$94 million, and US$251 million sales in emerging markets like India. The sale of Xalkori is declining as compared to FY2020 due to other treatment options by other market players and the high cost of the drug. However, potential approval for the drug’s label expansion into the hematologic indication will boost the drug’s sales further. Increased incidence of various cancers seems to create the opportunity for the future and burgeon the growth of the ROS 1 Inhibitor market. For instance, according to Centers for Disease Control and Prevention 2017, approximately 5,41,000 Americans living today have been diagnosed with lung cancer at some point in their lives. Moreover, among all regions Asia Pacific is expected to grow the fastest due to a rapidly growing economy, high cancer diagnosis rate, improving living standards, increasing consumer expenditure, and increasing R&D investment creating a lucrative opportunity for the ROS 1 Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Xalkori (Crizotinib), Lorbrena (Lorlatinib), Alunbrig (Brigatinib), etc are a few FDA-approved ROS 1 Inhibitor.
Major market players include Takeda, Pfizer, Roche, Xcovery, Eli Lilly are few leading market players.
Major Indications for ROS 1 inhibitors are lymphoma, tumors, leukemia, sarcoma, neutropenia, granuloma, lung neoplasm, ocular melanoma, etc.
There are a total of 16 molecules that are in Phase-1, Phase-2, and Phase-3 clinical development.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.